Although an accumulating body of evidence indicates that levels of prostaglandin E 2 (PGE 2 ) in human and rodent colon cancers are higher than those in surrounding normal tissues, the precise contribution of PGE 2 to the process of colon cancer development has still been unclear. Therefore, we designed a study using a well-established azoxymethane (AOM)-induced colon carcinogenesis in male F344 rat model to investigate whether administration of exogenous PGE 2 has a real impact on colon carcinogenesis. Intraperitoneal PGE 2 injections (7.7 mg) once a week for 25 weeks significantly increased the AOM-induced colon tumor incidence (percent rats with tumors, 92 versus 53%, P 5 0.05), especially adenocarcinomas (92 versus 47%, P 5 0.05), and multiplicity (number of tumors per rat, 2.8 versus 1.0, P 5 0.05). PGE 2 treatment significantly increased 5-bromo-2 H -deoxyuridine (BrdUrd) labeling index (11.8 versus 9.7%, P 5 0.05) and reduced apoptotic index (0.34 versus 0.53%, P 5 0.05) in colon cancers induced by AOM. PGE 2 exhibits its physiological functions through binding to E-prostanoid (EP) membrane receptors EP 1À4 . All four types of EP receptors were detected in AOM-induced colon cancers using reverse transcription± polymerase chain reaction (RT±PCR). Our results provide evidence that PGE 2 enhances colon carcinogenesis through induction of cell proliferation and reduction of apoptosis.
Cladosiphon fucoidan may deserve particular attention as a safe agent that can prevent H. pylori infection and reduce the risk of associated gastric cancer.
Levels of prostaglandin E(2) (PGE(2)) in human and rodent breast cancers are higher than surrounding normal tissues. PGE(2) exhibits biological activity through binding to membrane receptors, EP(1-4). The present study was designed to investigate the effects of ONO-8711, a newly synthesized selective PGE receptor EP(1) antagonist, on 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)-induced breast cancer development. Starting at 7 weeks of age, female Sprague-Dawley (SD) rats were given PhIP (85 mg/kg body weight) by gavage four times weekly for two weeks. Dietary administration of ONO-8711 at 400 or 800 p.p.m. delayed occurrence of breast tumors for 2 or 4 weeks, respectively. At 20 weeks after the last dosing of PhIP, all animals were killed and complete autopsy was made. All breast tumors were diagnosed as invasive ductal adenocarcinomas histopathologically. Administration of ONO-8711 at 800 p.p.m. significantly decreased PhIP-induced breast cancer incidence, multiplicity and volume compared with those of rats fed the control diet (56% versus 79%, P < 0.05, 1.2 versus 2.5, P < 0.05, 0.7 versus 1.4 cm(3), P < 0.01, respectively). Apoptosis was significantly increased in breast cancer cells by feeding of ONO-8711 at 800 p.p.m. of 158% (P < 0.05). EP(1) receptor was detected by reverse transcription-polymerase chain reaction (RT-PCR) in breast cancers, not in normal tissues. These results suggest that EP(1) receptor is associated with breast cancer development and selective PGE receptor EP(1) antagonists may possess chemopreventive effects through the induction of apoptosis without any side effects.
Cyclooxygenase (COX)-2, one enzyme isoform responsible for producing prostanoids from arachidonic acid, contributes to colon carcinogenesis. Recently, genetic disruption of COX-1, the other isoform, was shown to decrease the number of intestinal polyps and prostaglandin E(2) levels in intestinal mucosa, like the case with COX-2 gene disruption, in Min mice. We therefore investigated whether a COX-1 selective inhibitor, mofezolac, suppresses intestinal carcinogenesis in rodents. F344 male rats, receiving azoxymethane (AOM, 15 mg/kg body wt) s.c. injections at 5 and 6 weeks of age, were fed a diet containing 600 or 1200 p.p.m. mofezolac for 4 weeks. The number of aberrant crypt foci (ACFs) per rat and the bromodeoxyuridine labeling index of the crypt epithelium were dose-dependently decreased by administration of mofezolac, the value for the former at 1200 p.p.m. being 60% of control value. When Apc gene knockout mice (APC1309 mice) were given 600 or 1200 p.p.m. mofezolac in their diet for 8 weeks, the numbers of intestinal polyps were also dose-dependently decreased, with reduction to 59% of that in the control diet group at the higher dose. Nimesulide, a COX-2 selective inhibitor used as positive control, showed similar suppressive effects on the development of ACFs in AOM-treated rats and polyps in Apc gene knockout mice. The data indicate that both COX-1 and COX-2 can contribute to intestinal tumorigenesis.
A novel mutagenic compound, 9-(4'-aminophenyl)-9H- pyrido[3,4-b]indole (aminophenylnorharman, APNH), is shown to be formed by the in vitro enzymatic reaction of 9H-pyrido[3,4-b]indole (norharman) and aniline. APNH generates DNA adducts (dG-C8-APNH), and is potently genotoxic to bacteria and mammalian cells. APNH has also been demonstrated to be formed in vivo from norharman and aniline, and suggested to be a new type of endogenous mutagenic compound. To determine its carcinogenic activity, long-term administration of APNH was investigated in 93 male and 90 female F344 rats. Rats were fed diets containing 0, 20 or 40 p.p.m. from 7 weeks of age. All animals were killed after 85 weeks treatment and necropsy was performed. Hepatocellular carcinomas (HCCs) were induced at incidences of 10 and 79% in male rats fed 20 and 40 p.p.m. APNH, and 34% in female rats fed 40 p.p.m. of APNH, respectively. In addition, colon adenocarcinomas were found at incidences of 3 and 9% in male rats, and 4 and 13% in female rats fed 20 and 40 p.p.m. of APNH, respectively. Other tumors, including thyroid carcinomas and mononuclear cell leukemia, were also seen in rats fed APNH. Polymerase chain reaction-single strand conformation polymorphism analysis revealed beta-catenin gene mutations in 24% of HCCs and K-ras, beta-catenin and Apc gene mutations were found in 22, 44 and 33% of colon cancers induced by APNH, respectively. Most mutations occurred at G:C base pairs. beta-Catenin protein accumulations in the nucleus and cytoplasm were also revealed in both liver and colon tumors. Thus, APNH induced liver and colon cancers with K-ras, beta-catenin and Apc gene mutations in F344 rats.
Patients with dominantly inherited Li-Fraumeni syndrome have a loss-of-function mutation
in
TP53
and develop diverse mesenchymal and epithelial neoplasms at
multiple sites.
Trp53
+/−
female mice with the BALB/c
background provide unique characteristics for the study of breast cancer in Li-Fraumeni
syndrome; however, we previously found that female
C3H-
Trp53
+/
−
mice did not spontaneously develop
mammary tumors. Therefore, we obtained F1 and N2-N4 female mice by backcrossing the BALB/c
strain and examined the incidence of mammary and other tumors in lifetime studies.
Malignant lymphomas, osteosarcomas, and uterine adenocarcinomas spontaneously developed in
approximately 20% or more of
Trp53
+/
−
mice with the
C3H background. In contrast, the incidence of uterine adenocarcinomas showed a tendency to
decrease, while that of mammary adenocarcinomas gradually increased in mice with the
BALB/c strain backcross. Wild-type BALB/c female mice are predisposed to a wide spectrum
of neoplasms, including mammary tumors, partly due to genetic factors, whereas uterine
tumors are uncommon not only in BALB/c mice but also C3H mice. Thus, genetic factors
appear to contribute to a strain-specific predisposition to malignant neoplasms in
Trp53
+/−
mice, and further studies are needed to clarify
the detailed mechanisms.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.